Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenp53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Annexin/S100A Protein Family Regulation through p14ARF-p53 Activation: A Role in Cell Survival and Predicting Treatment Outcomes in Breast CancerChanges in allelic imbalances in locally advanced breast cancers after chemotherapy.Targeting p53 for Novel Anticancer Therapy.TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions.p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.TP53 status and response to treatment in breast cancersExpression of C-terminal deleted p53 isoforms in neuroblastoma.Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.Breast cancer biomarkers and molecular medicine: part II.Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.Treatment-induced cell cycle kinetics dictate tumor response to chemotherapyTLR4 has a TP53-dependent dual role in regulating breast cancer cell growth.Evaluation of biological pathways involved in chemotherapy response in breast cancer.Updates on p53: modulation of p53 degradation as a therapeutic approachp53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression.Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.Clinical outcomes based on multigene profiling in metastatic breast cancer patientsMolecular basis for therapy resistance.Possibilities to increase the effectiveness of doxorubicin in cancer cells killing.The mutant p53 mouse as a pre-clinical model.p53 as an Effector or Inhibitor of Therapy Response.Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence.Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients.GABAB receptor regulates proliferation in the high-grade chondrosarcoma cell line OUMS-27 via apoptotic pathways.Cancer biology: Can less be more for p53?
P2860
Q21092375-ED381B3A-7C26-424A-9501-6E07DE05DFECQ27851827-85ACFD28-84AD-419C-A671-2AFB65E4E076Q28468360-779BD702-E934-4F0B-A863-F414A1252BE9Q33299319-17ACCF23-2D18-4E3A-A6B3-E65F5BB1D421Q33655329-DF2DED22-BED2-43B4-9CBB-CD92E86EBDBFQ34234217-1E7E1E96-387C-4231-8779-2D6522E326D0Q34961997-F69102BF-D14C-402C-A563-02681E577785Q35029530-9C97E217-6413-4225-B659-BB427EAC6B21Q35043933-247D9B94-CB04-4302-84BA-03EC664F6DE8Q35130560-16289D64-6EAF-4968-9457-F9C7FB0A636EQ35161695-2B4D2DAD-73BB-4BF3-93C9-41D493B289F3Q35583968-EE7E09EF-90E6-4BCD-AE7B-A1C46BC85DD7Q35605783-219D235E-A0C9-410C-8CDE-CECC9F05B4B3Q35680309-E5F56CB4-B7E2-4FC5-AF9A-23A1714C5479Q35737352-B6E010A8-C7C9-43B4-9B78-EF4DB51D624EQ35740145-2A22AF5E-E258-4B3A-AA14-44519A6D7CAAQ35796070-89C92C8E-D39B-45E8-8131-6EB5A8F8E1D2Q36678725-ED556A46-7446-4415-A440-15EFF4D4D052Q37053528-E8E5D29F-3B27-497C-B296-D5D6F40D2631Q37549455-4D556156-A354-4045-AD0B-A258CEB59060Q37650748-3702355F-C8CC-4661-9975-1DC0B5711269Q37718221-FAC5D0D5-67AB-4EE7-B957-79296516D2A5Q37751530-230B5CEA-6C20-4EA6-857E-9907714F16B6Q37937579-E8DFD1E7-369E-4527-A4F4-2EC848D4DFB1Q38074014-CFB4BBFF-E12E-4628-AB54-B7545C5D563DQ38659283-02C4B2A8-82C1-494F-A0B1-4B070C4A2240Q38809821-A38BFE30-330E-428C-8A7E-FB90CAB0B606Q39018419-B93532DA-F482-4515-B226-222D91F7FA1CQ39459198-84049379-51A2-4FDB-AC78-7E28AFEC309FQ41519051-F3D2594B-AAA4-43DB-84AF-DB58D1F89170Q42315543-D0DCEA9A-DCCF-46E2-841F-C9EA2C64BDEDQ46511043-269D5016-D80D-41EF-9C46-60D199CD82C1Q52668912-7012A50E-53DE-4E7F-96A7-DE68CB750588Q59007923-37D2F1E8-EC6C-42BF-BDA2-BB7116C864D1
P2860
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
@en
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
@nl
type
label
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
@en
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
@nl
prefLabel
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
@en
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
@nl
P2093
P1433
P1476
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
@en
P2093
A de Roquancourt
F Lerebours
P Bertheau
P304
P356
10.1016/S0140-6736(02)09969-5
P407
P577
2002-09-01T00:00:00Z